Tarsus Pharmaceuticals Shares Soar 2.78% After Analyst Upgrades

Tarsus Pharmaceuticals, Inc. (TARS) shares surged 2.78% today, marking a significant rebound after hitting a low not seen since October 2024, with an intraday decline of 9.52%.

Analysts have recently updated their ratings and price targets for Tarsus Pharmaceuticals. Oppenheimer increased their price objective from $65.00 to $72.00 with an "outperform" rating. HC Wainwright maintained a "buy" rating with a $73.00 target price. Guggenheim raised their price target from $75.00 to $78.00, while Barclays lowered their price target from $62.00 to $60.00 but maintained an "overweight" rating. Jefferies Financial Group raised their target price from $54.00 to $58.00 with a "buy" rating. Overall, the company has an average rating of "Buy" and an average price target of $63.67.

Significant changes in institutional holdings have been reported. Vanguard Group Inc. increased its stake by 0.9% during the fourth quarter. Other institutional investors like R Squared Ltd, FMR LLC, HighTower Advisors LLC, Victory Capital Management Inc., and Oppenheimer & Co. Inc. have also modified their holdings, indicating active interest and investment in Tarsus Pharmaceuticals.

Recent insider selling activities have been noted, with General Counsel Bryan Wahl and insider Dianne C. Whitfield selling shares in March. These transactions resulted in a reduction of their ownership stakes by 5.44% and 4.41%, respectively. This insider selling could be a cause for concern among investors, as it may indicate a lack of confidence in the company's future prospects.

Tarsus Pharmaceuticals reported earnings with a revenue of $66.41 million for the last quarter, exceeding consensus estimates. However, the company continues to post a negative return on equity and net margin, which may contribute to stock volatility. The mixed financial performance, coupled with the recent insider selling, suggests a cautious outlook for the company despite the positive analyst sentiment and active institutional involvement.